The VC is funded mainly via Rigmora Biotech Investor One and Rigmora Biotech Investor Two, according to a June 27 press release. Both funds are part of Rigmora Holdings, a family office that manages ...

Gyre Therapeutics has a unique business model for evaluating and commercializing drugs in China. Find out why GYRE stock is a ...

Although the SYMMETRY Phase IIb trial of the FGF21 analogue efruxifermin did not meet its primary endpoint at 36 weeks, ...

Pfizer will pay a $0.43 quarterly dividend on September 2, 2025, maintaining its 347-quarter streak of shareholder payouts.

Perspective Therapeutics, Inc. announced two presentations showcasing their advancements in cancer treatments at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting ...

Andrew Cheng, President and CEO of Akero Therapeutics, Inc. (NASDAQ: AKRO), sold 6,620 shares of common stock on June 18, 2025, according to a Form 4 filing with the Securities and Exchange Commission ...

William Richard White, Chief Financial Officer of Akero Therapeutics, Inc. (NASDAQ: AKRO), sold 1,634 shares of common stock on June 18, 2025, according to a Form 4 filing with the Securities and ...

Akero Therapeutics, Inc. (NASDAQ: AKRO), a $4.35 billion market cap biotech company whose stock has surged 133% over the past year, reported that Chief Scientific Officer Timothy Rolph sold 1,129 ...

Akero Therapeutics (NASDAQ: AKRO) Chief Development Officer Yale Catriona sold 1,633 shares of common stock on June 18, 2025, according to a Form 4 filing with the Securities and Exchange Commission.